---
reference_id: "PMID:38182298"
title: "A new alternative: inhibiting complement activation in patients with IgA nephropathy."
authors:
- Floege J
journal: Kidney Int
year: '2024'
doi: 10.1016/j.kint.2023.10.012
content_type: abstract_only
---

# A new alternative: inhibiting complement activation in patients with IgA nephropathy.
**Authors:** Floege J
**Journal:** Kidney Int (2024)
**DOI:** [10.1016/j.kint.2023.10.012](https://doi.org/10.1016/j.kint.2023.10.012)

## Content

1. Kidney Int. 2024 Jan;105(1):28-30. doi: 10.1016/j.kint.2023.10.012.

A new alternative: inhibiting complement activation in patients with IgA 
nephropathy.

Floege J(1).

Author information:
(1)Division of Nephrology and Immunology, RWTH University of Aachen, Aachen, 
Germany. Electronic address: jfloege@ukaachen.de.

Comment on
    Kidney Int. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027.

Mesangial complement C3 deposits, reflecting alternative and possibly lectin 
pathway activation, are characteristic in biopsies of patients with IgA 
nephropathy (IgAN). A recent randomized controlled trial tested the efficacy and 
safety of iptacopan, a factor B inhibitor, in patients with IgAN. Iptacopan 
dose-dependently reduced proteinuria, and there was a pronounced decrease of 
urinary C5b-9. This offers the perspective of "personalizing" therapy, which 
would be a unique feature of this novel approach to IgAN. A phase III clinical 
trial (APPLAUSE-IgAN) is ongoing.

Copyright Â© 2023 International Society of Nephrology. Published by Elsevier Inc. 
All rights reserved.

DOI: 10.1016/j.kint.2023.10.012
PMID: 38182298 [Indexed for MEDLINE]